Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 6 (June)

1. Annotation of androgen dependence to human prostate cancer-associated genes by microarray analysis of mouse prostate.
   Cancer Lett, 237(2): 298-304. [Abstract] [Full-text]
2. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history.
   J Med Genet, 43(6): 507-11. [Abstract] [Full-text]
3. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
   Lancet Oncol, 7(6): 472-9. [Abstract] [Full-text]
4. A comparison of CT- and ultrasound-based imaging to localize the prostate for external beam radiotherapy.
   Int J Radiat Oncol Biol Phys, 65(3): 678-87. [Abstract] [Full-text]
5. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.
   Int J Radiat Oncol Biol Phys, 65(3): 669-77. [Abstract] [Full-text]
6. Predictors of mortality after prostate-specific antigen failure.
   Int J Radiat Oncol Biol Phys, 65(3): 656-60. [Abstract] [Full-text]
7. Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography.
   Int J Radiat Oncol Biol Phys, 65(3): 688-93. [Abstract] [Full-text]
8. Permanent prostate brachytherapy: Dosimetric results and analysis of a learning curve with a dynamic dose-feedback technique.
   Int J Radiat Oncol Biol Phys, 65(3): 694-8. [Abstract] [Full-text]
9. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer.
   Int J Radiat Oncol Biol Phys, 65(3): 661-8. [Abstract] [Full-text]
10. Critical roles of AMP-activated protein kinase in the carcinogenic metal-induced expression of VEGF and HIF-1 proteins in DU145 prostate carcinoma.
    Biochem Pharmacol, 72(1): 91-103. [Abstract] [Full-text]
11. Predicting prostate biopsy results: The importance of PSA, age, and race.
    Am J Clin Pathol, 126(1): 110-2. [Abstract] [Full-text]
12. Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
    J Urol, 176(1): 354-60. [Abstract] [Full-text]
13. Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy.
    J Urol, 176(1): 257-61; discussion 261-2. [Abstract] [Full-text]
14. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy.
    J Urol, 176(1): 91-5. [Abstract] [Full-text]
15. Hyperbaric oxygen therapy for radiation induced proctopathy in men treated for prostate cancer.
    J Urol, 176(1): 87-90. [Abstract] [Full-text]
16. Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.
    J Urol, 176(1): 81-6. [Abstract] [Full-text]
17. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
    J Urol, 176(1): 75-80. [Abstract] [Full-text]
18. Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?
    J Urol, 176(1): 70-3; discussion 73-4. [Abstract] [Full-text]
19. Impact of increased number of biopsies on the nature of prostate cancer identified.
    J Urol, 176(1): 63-8; discussion 69. [Abstract] [Full-text]
20. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
    J Natl Cancer Inst, 98(11): 783-93. [Abstract] [Full-text]
21. Effect of capsazepine on cytosolic Ca(2+) levels and proliferation of human prostate cancer cells.
    Toxicol In Vitro, 20(5): 567-74. [Abstract] [Full-text]
22. Prostasome-derived proteins capable of eliciting an immune response in prostate cancer patients.
    Int J Cancer, 119(4): 847-53. [Abstract] [Full-text]
23. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.
    Int J Cancer, 119(5): 1082-7. [Abstract] [Full-text]
24. Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
    Am J Physiol Cell Physiol, 291(1): C40-9. [Abstract] [Full-text]
25. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
    J Clin Oncol, 24(18): 2828-35. [Abstract] [Full-text]
26. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
    J Clin Oncol, 24(18): 2723-8. [Abstract] [Full-text]
27. Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells.
    Biochem Biophys Res Commun, 346(2): 447-53. [Abstract] [Full-text]
28. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
    J Natl Cancer Inst, 98(12): 839-45. [Abstract] [Full-text]
29. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
    Int J Radiat Oncol Biol Phys, 65(4): 965-74. [Abstract] [Full-text]
30. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension?
    Int J Radiat Oncol Biol Phys, 65(4): 999-1007. [Abstract] [Full-text]
31. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.
    Int J Radiat Oncol Biol Phys, 65(4): 975-81. [Abstract] [Full-text]
32. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.
    Int J Radiat Oncol Biol Phys, 65(4): 982-9. [Abstract] [Full-text]
33. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.
    Int J Radiat Oncol Biol Phys, 65(4): 1008-13. [Abstract] [Full-text]
34. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
    Int J Radiat Oncol Biol Phys, 65(4): 1014-9. [Abstract] [Full-text]
35. Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 65(4): 990-8. [Abstract] [Full-text]
36. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
    J Clin Oncol, 24(19): 3089-94. [Abstract] [Full-text]
37. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment.
    J Clin Oncol, 24(19): 3081-8. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.